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S U M M A R Y
Objectives: Previous studies on the tumor necrosis factor-a (TNF-a)-308 gene promoter polymorphism
in chronic hepatitis B virus (HBV) infection have reported conﬂicting results.
Methods: We carried out a meta-analysis of 21 studies in relation to the TNF-a-308 gene promoter,
involving a total of 4230 chronic HBV infection cases and 2905 controls.
Results: The overall meta-analysis indicated that 308A heterozygotes (GA) had a signiﬁcant 27%
decreased risk of developing chronic hepatitis B (CHB) (odds ratio (OR) 0.73; 95% conﬁdence interval (CI)
0.57–0.93; p = 0.012). For 308A allele homozygotes (AA) and carriers (GA+AA), the pooled odd ratios
both indicated a signiﬁcantly decreased risk of CHB (OR 0.28; 95% CI 0.19–0.43; p = 0.0001; and OR 0.70;
95% CI 0.55–0.89; p = 0.004, respectively). In subgroup analyses by ethnicity, a signiﬁcantly decreased
risk was associated with 308 variant genotypes (GA and AA) in Mongoloid populations in all genetic
models. However, no signiﬁcant associations were found in Caucasoids. Moreover, in the subgroup
analyses by control group, signiﬁcantly decreased risk was associated with 308 variant genotypes (GA
and AA) in the group of spontaneously recovered cases in all genetic models; however, no signiﬁcant
associations were found in the group of healthy cases.
Conclusions: TheTNF-a-308Aallele isaprotective factor for chronicHBVinfection, especially inMongoloids.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B is becoming a severe public health problem that
should be resolved with urgency. It is estimated that there are
more than 350 million people infected with the hepatitis B virus
(HBV) worldwide.1 HBV infection causes various clinical outcomes
in patients; 90–95% of adults infected with HBVmight successfully
eliminate the virus through self-limiting hepatitis and only 5–10%
of them become chronic HBV carriers; 20–30% of the chronic
infections lead to liver cirrhosis and 5% develop hepatocellular
carcinoma in a long run of disease course.2
The risk of progression to chronic hepatitis depends on several
factors: viral strain, genotype, and host factors such as age, gender,
ethnic background, immune status, etc.3,4 Several cytokines that§ Data in this article were presented in poster form at the Second Ditan
International Conference on Infectious Diseases, Beijing, China, November 14–17,
2008 (published in Int J Infect Dis 2008;12:S62).
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doi:10.1016/j.ijid.2009.08.010participate in the process of viral clearance via host immune
response to HBV have been identiﬁed.5 In particular, tumor
necrosis factor-a (TNF-a) is an important cytokine in the immune
pathogenesis of HBV infection. The TNF-a gene is located 850 kb
telomeric of the class III HLA-DR locus of the short arm of
chromosome 6, and is closely linked to human leukocyte antigen
(HLA) gene clusters.6 Recent evidence suggests that TNF-a can
induce the non-cytolytic suppression of HBV expression and
replication in the liver.7 TNF-a can also inhibit the transcriptional
activity of the HBV core promoter in vitro.8 Moreover, TNF-a
affects the expression of HLA-II molecules, and hence, viral antigen
presentation.9
The polymorphisms in the promoter region of the TNF-a gene
have been extensively studied in relation to HBV infection. To date,
there have been 181 single nucleotide polymorphisms (SNPs) in
the TNF-a gene reported in the National Center for Biotechnology
Information (NCBI) database, with more than 10 SNPs in the
promoter region, including those at 163G/A, 238G/A,244A/G,
308G/A, 376G/A, 575A/G, 857C/T, 863C/A, 1031T/C,
1125G/C, and 1196C/T base pairs from the transcription start
site.10–13 The 308 polymorphism in the TNF-a gene has beenses. Published by Elsevier Ltd. All rights reserved.
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associated with an increased production of TNF-a,14 which is a
central mediator of the immune response.
Considerable evidence suggests that TNF-a-308 gene promoter
polymorphism is associated with clearance or susceptibility of
chronic HBV infection.15–35 However, association studies have
many limitations and often give inconsistent results. These studies
are based on limited sample size, and participant characteristics
(such as ethnicity, age, gender, etc.) are different from each other.
Therefore, every single study may be underpowered to achieve a
comprehensive and reliable conclusion.
To better address the association between the commonly
studied TNF-a-308 gene promoter with susceptibility to chronic




Epidemiological genetic association studies published before
July 2008 on HBV infection and polymorphism in the TNF-a-308
gene promoter were sought by computer-based searches, scanning
of the reference lists of articles identiﬁed for all relevant studies
and review articles (including meta-analyses), hand-searching of
relevant journals, and correspondence with authors of included
studies. Computer searches of PubMed, Web of Science, EMBASE,
and the China Biological Medicine Database (CBMdisc) used
keywords related to the TNF-a-308 gene in combination with
words related to HBV infection and polymorphism, without
language restriction. All relevant studies identiﬁed were included
apart from ﬁve in which the data were duplicated or overlapped.
Inclusion criteria
The inclusion criteria were: (1) evaluation of the TNF-a-308
gene promoter polymorphism and chronic HBV infection, (2) case–Table 1
Main characteristics of all studies included in the meta-analysis
First author (year) Region Genotyping method
Basturk (2008)15 Turkey PCR-SSP
Tao (2008)16 China, Yunnan PCR-RFLP
Kummee (2007)17 Thailand PCR-RFLP
Xing (2007)18 China, Shandong Gene chips
Du (2006)19 China, Beijing PCR-RFLP, SSP
Cheong (2006)20 Korea SBPEA
Somi (2006)21 Iran PCR-RFLP
Li (2006)22 China, Fujian PCR-SSP
Suneetha (2006)23 India PCR-RFLP, SSP
Xu (2005)24 China, Hunan PCR-RFLP
Niro (2005)25 Italy DS
Liu (2005)26 China, Beijing PCR-RFLP
Mao (2005)27 China, Gansu AS-PCR allele-speciﬁc P
Zhang (2005)28 China, Hubei PCR-RFLP
Zhou (2005)29 China, Beijing PCR-RFLP
Zhang (2004)30 China, Hubei PCR-RFLP
Ben-Ari (2003)31 Israel PCR-SSP
Kim (2003)32 Korea SBPEA
Lin (2002)33 China, Hubei PCR-RFLP
Miyazoe (2002)34 Japan PCR-RFLP, DS
Hohler (1998)35 Germany Hybridization
CI, chronic infection, including asymptomatic carriers, chronic hepatitis B, and liver cirrh
polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequenccontrol studies, and (3) sufﬁcient published data for estimating an
odds ratio (OR) with 95% conﬁdence interval (CI).
Deﬁnitions
The deﬁnition of spontaneously recovered (SR) infection was as
follows: positive for both anti-hepatitis B surface antigen (anti-
HBs) antibodies and anti-hepatitis B core antigen (anti-HBc)
antibodies, deﬁnitely negative for hepatitis B surface antigen
(HBsAg), normal liver function tests, and no history of acute/
chronic hepatitis B and HBV vaccination. Chronic hepatitis B (CHB)
was diagnosed if serum levels of alanine aminotransferase (ALT)
and aspartate aminotransferase (AST)were continuously abnormal
and HBsAg was seropositive without anti-HBs from the sixth
month of acute infection. An asymptomatic carrier was a person
who had contracted HBV, but who displayed no symptoms.
Chronic infection included asymptomatic carriers, chronic hepa-
titis B, and liver cirrhosis.
Data abstraction
The following information was abstracted from each study,
according to a ﬁxed protocol: study design, geographical location,
ethnic group of participants, deﬁnition and numbers of cases and
controls, DNA extraction and genotyping methods, frequency of
genotypes, mean age of cases, and proportion of cases who were
male. Different ethnicity descents were categorized as Caucasoid
(e.g., people of European continental ancestry) and Mongoloid (e.g.,
people of East Asia, etc.). When studies included subjects of more
than one ethnicity, genotype data were extracted separately. The
control group was divided into an SR group and a healthy group.
Information was carefully extracted from all eligible publications
independently by two of the authors (Zheng and Qiu) according to
the inclusion criteria listed above. Disagreement was resolved by
discussionbetween the twoauthors. If twoauthors couldnot reacha
consensus, another author (Chen) was consulted to resolve the
dispute and a ﬁnal decision was made by a majority vote.Cases Controls
Sample n Sample n
CI 50 Healthy 60
CI 102 Healthy 49
CI 150 SR 100
Healthy 150
CI 150 SR 100
CHB 196 SR 143
CI 412 SR 204
CI 100 Healthy 89
SR 91
CI 122 Healthy 63
CI 214 Healthy 408
CI 127 Healthy 90
CI 184 SR 96
CHB 207 SR 148
CR CHB 156 Healthy 80
CHB 131 Healthy 126
CI 222 Healthy 103
CHB 131 SR 165
CI 77 SR 10
Healthy 48
CI 1109 SR 291
LC 106 Healthy 108
CI 213 Healthy 52
CHB 71 Healthy 99
SR 32
osis; CHB, chronic hepatitis B; LC, liver cirrhosis; SR, spontaneously recovered; PCR,
e-speciﬁc primer; DS, direct sequencing; SBPEA, single-base primer extension assay.
Table 2
Detailed information of genotype GG, GA, and AA in the studies included in the meta-analysis
First author (year) Ethnicity (country) Case Control
AA, n (%) GA, n (%) GG, n (%) AA, n (%) GA, n (%) GG, n (%)
TNF-a-308 polymorphism (control = spontaneously recovered)
Xing (2007)18 Mongoloid (China) 30 (20.0) 75 (50.0) 45 (30.0) 35 (35.0) 59 (59.0) 6 (6.0)
Kummee (2007)17 Mongoloid (Thailand) 0 (0) 22 (14.7) 128 (85.3) 0 (0) 18 (18) 82 (82)
Somi (2006)21 Caucasoid (Iran) 2 (2) 20 (20) 78 (78) 1 (1) 20 (22) 70 (77)
Du (2006)19 Mongoloid (China) 2 (1.03) 15 (7.65) 179 (91.33) 5 (3.5) 10 (6.99) 128 (89.51)
Cheong (2006)20 Mongoloid (Korea) 1 (0.25) 45 (10.92) 366 (88.83) 1 (0.5) 28 (13.7) 175 (85.8)
Liu (2005)26 Mongoloid (China) 2 (1.0) 16 (8.0) 182 (91.0) 5 (3.5) 10 (6.9) 129 (89.6)
Niro (2005)25 Caucasoid (Italy) 2 (1) 28 (15) 154 (84) 0 (0) 21 (22) 75 (78)
Zhang (2004)30 Mongoloid (China) 0 (0) 6 (4.6) 125 (95.4) 0 (0) 22 (13.3) 143 (86.7)
Kim (2003)32 Mongoloid (Korea) 1 (0.1) 68 (6.5) 971 (93.4) 0 (0) 32 (11.3) 251 (88.7)
Ben-Ari (2003)31 Caucasoid (Israel) 0 (0) 13 (16.9) 64 (83.1) 0 (0) 2 (20.0) 8 (80.0)
Hohler (1998)35 Caucasoid (Germany) 3 (4) 21 (30) 47 (66) 0 (0) 10 (31) 22 (69)
TNF-a-308 polymorphism (control =healthy)
Tao (2008)16 Mongoloid (China) 3 (2.9) 3 (2.9) 96 (94.2) 5 (10) 0 (0) 44 (90)
Basturk (2008)15 Caucasoid (Turkey) 0 (0) 5 (10.0) 45 (90.0) 4 (6.7) 17 (28.3) 39 (65.0)
Kummee (2007)17 Mongoloid (Thailand) 0 (0) 22 (14.7) 128 (85.3) 1 (0.6) 26 (17.3) 123 (82)
Suneetha (2006)23 Caucasoid (India) 1 (0.4) 65 (30.4) 148 (69.2) 2 (0.5) 136 (33.3) 270 (66.2)
Somi (2006)21 Caucasoid (Iran) 2 (2) 20 (20) 78 (78) 1 (1) 13 (15) 75 (84)
Li (2006)22 Mongoloid (China) 0 (0) 31 (25.4) 91 (74.6) 0 (0) 19 (30.2) 44 (69.8)
Zhou (2005)29 Mongoloid (China) 0 (0) 19 (8.6) 203 (91.4) 0 (0) 20 (19.4) 83 (80.6)
Zhang (2005)28 Mongoloid (China) 0 (0) 6 (4.6) 125 (95.4) 0 (0) 18 (14.3) 108 (85.7)
Xu (2005)24 Mongoloid (China) 0 (0) 20 (15.7) 107 (84.3) 0 (0) 10 (11.1) 80 (88.9)
Mao (2005)27 Mongoloid (China) 38 (24.3) 72 (46.2) 46 (29.5) 36 (40.9) 48 (54.5) 4 (4.5)
Ben-Ari (2003)31 Caucasoid (Israel) 0 (0) 13 (16.9) 64 (83.1) 0 (0) 6 (12.5) 42 (87.5)
Miyazoe (2002)34 Mongoloid (Japan) 0 (0) 6 (3) 207 (97) 0 (0) 2 (4) 50 (96)
Lin (2002)33 Mongoloid (China) 0 (0) 21 (19.8) 85 (80.2) 0 (0) 11 (10.2) 97 (89.8)
Hohler (1998)35 Caucasoid (German) 3 (4) 21 (30) 47 (66) 6 (6) 20 (20) 73 (74)
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ORs with 95% CIs were applied to assess the strength of
association of TNF-a-308 gene promoter polymorphism with
chronic HBV infection. The unadjusted OR of each study was ﬁrst
calculated in a 2  2 table. The pooled ORs for the risk associated
with the genotypes of GA, AA, and GA+AA (A-allele carriers)
compared with the GG genotype were calculated. One-way
sensitivity analyses were performed to assess the stability of the
results, namely, a single study in the meta-analysis was deleted
each time to reﬂect the inﬂuence of the individual data-set to the
pooled OR.36 Heterogeneity was evaluated using the Chi-square
test.37 A p-value of <0.1 was considered signiﬁcant for hetero-
geneity. Fixed-effect models (Mantel–Haenszel method) were
used throughout, unless statistical heterogeneity was signiﬁcant,
in which case, a random-effects model (DerSimonian and Laird
method) was used. The signiﬁcance of the pooled OR was
determined by the Z-test, and p < 0.05 was considered as
statistically signiﬁcant. An estimate of potential publication bias
was carried out by funnel plot, in which the standard error of
log(OR) of each study was plotted against its log(OR). An
asymmetric plot suggests a possible publication bias. Funnel plot
asymmetry was assessed by the method of Egger’s linearTable 3
Main results of pooled odds ratios in the meta-analysis
GA vs. GG AA vs. GG
OR (95% CI) p-Value p-Value
(Q-test)a
OR (95% CI)
Total 0.73 (0.57, 0.93) 0.012 0.0001 0.28 (0.19, 0.43)
Mongoloid 0.64 (0.46, 0.90) 0.009 0.0001 0.16 (0.10, 0.28)
Caucasoid 0.91 (0.73, 1.14) 0.408 0.185 0.93 (0.43, 1.99)
SR 0.67 (0.50, 0.89) 0.006 0.080 0.31 (0.17, 0.54)
Healthy 0.79 (0.54, 1.16) 0.230 0.0001 0.26 (0.14, 0.47)
OR, odds ratio; CI, conﬁdence interval; SR, spontaneously recovered.
a p-Value (Q-test): p-Value of Q-test for heterogeneity. A random-effects model was
model was used.regression test, a linear regression approach to measure funnel
plot asymmetry on the natural logarithm scale of the OR. The
signiﬁcance of the intercept was determined by the t-test
suggested by Egger (p < 0.05 was considered representative of
statistically signiﬁcant publication bias).38
Analysis was performed using the statistical software Inter-
cooled Stata version 8.0 for Windows (Stata Corporation, College
station, TX, USA). All p-values were two-sided.
Results
Twenty-one studieswith a total number of 4230 cases and 2905
controls were included in this analysis (Tables 1 and 2).15–35 All
studies used healthy volunteers or SR patients as control subjects.
In four of these studies,17,21,31,35 the ORswere presented separately
according to the different control groups (Tables 1 and 2). Sample
sizes in the 21 studies ranged from 110 to 1400. There were six
studies of Caucasoids15,21,23,25,31,35 and 15 studies of Mongo-
loids.16–20,22,24,26–30,32–34 Almost all of the cases were histologi-
cally conﬁrmed. No signiﬁcant differences were found in the age
distributions between the cases and controls. Genotypingmethods
used in the studies included PCR-restriction fragment length
polymorphism (RFLP), PCR- sequence speciﬁc primer (SSP), single-GA+AA vs. GG
p-Value p-Value
(Q-test)a
OR (95% CI) p-Value p-Value
(Q-test)a
0.0001 0.125 0.70 (0.55, 0.89) 0.004 0.0001
0.0001 0.718 0.59 (0.43, 0.82) 0.002 0.0001
0.842 0.672 0.91 (0.73, 1.14) 0.409 0.121
0.0001 0.159 0.65 (0.49, 0.86) 0.003 0.062
0.0001 0.137 0.73 (0.50, 1.08) 0.115 0.0001
used when the p-value for heterogeneity test was <0.1; otherwise, a ﬁxed-effects
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gene chips. The frequency of GG genotype was 77.0% in Caucasoids
and 85.5% in Mongoloids; the frequency of the GA genotype was
21.8% in Caucasoids and 12.3% inMongoloids; and the frequency of
the AA genotype was 1.2% in Caucasoids and 2.2% in Mongoloids.
We found the 308G/G genotype in 73.8% of our healthy
volunteers in the meta-analysis, a rate that is different from the
prevalence rates reported in different regions of the world. The
rates reported were 60.5% in southeast England, 77–78% in Italy,
81.6% in Gambia and 96% in Japan.11,25,39,40
Meta-analysis results
The overall meta-analysis indicated that 308A heterozygotes
(GA) had a signiﬁcant, approximately 27% decreased risk of
developing CHB (OR 0.73; 95% CI 0.57–0.93; p = 0.012). For the
homozygotes (AA) and the 308A allele carriers (GA+AA), the
pooled ORs indicated a signiﬁcantly decreased risk of CHB (OR
0.28; 95% CI 0.19–0.43; p = 0.0001; and OR 0.70; 95% CI 0.55–0.89;
p = 0.004, respectively). In the subgroup analyses by ethnicity, a
signiﬁcantly decreased risk was associated with 308 variant
genotypes (GA and AA) in Mongoloid populations in all geneticFigure 1. Forest plot of chronic hepatitis B virus infection risk associated with TNF-a-30
pooled odds ratios indicated a signiﬁcantly decreased risk of chronic hepatitis B (OR 0.7
decreased risk was associated with 308 variant genotypes (GA and AA) in Mongol
associations were found in Caucasoids. OR: odds ratio; CI: conﬁdence interval.models (Table 3 and Figure 1). However, no signiﬁcant associations
were found in Caucasoids (Table 3). Moreover, in the subgroup
analyses according to the control group, a signiﬁcantly decreased
risk was associated with 308 variant genotypes (GA and AA) in
the SR control group in all genetic models (Table 3); however, no
signiﬁcant associations were found in the healthy control group
(Table 3). The Q-test suggested signiﬁcant between-study hetero-
geneity in all the comparisons except for Caucasoids (Table 3).
Although the genotype distribution in the seven studies did not
follow Hardy–Weinberg equilibrium,16,18,19,23,26,27,35 the corre-
sponding pooled ORs were not materially altered with or without
including these studies (data not shown). Similarly, no other single
study inﬂuenced the pooled OR qualitatively as indicated by
sensitivity analyses.
Publication bias
Begg’s funnel plot and Egger’s test were performed to assess the
publication bias of the literature. The shapes of the funnel plots did
not reveal evidence of obvious asymmetry in all comparison
models (Figure 2). The Egger’s test results suggested that
publication bias was evident for AA vs. GG (p = 0.003), but not8G/A polymorphism for GA+AA vs. GG. For the 308A allele carriers (GA+AA), the
0; 95% CI 0.55–0.89; p = 0.004). In the subgroup analyses by ethnicity, signiﬁcantly
oid populations (OR 0.59; 95% CI 0.43–0.82; p = 0.002). However, no signiﬁcant
Figure 2. Begg’s funnel plot (using odds ratio of chronic hepatitis B virus infection
risk in GA+AA genotype when compared to GG genotype) of TNF-a-308G/A
polymorphism and chronic hepatitis B virus infection risk for the genotype GA+AA
vs. GG (p = 0.300). The horizontal line represents the meta-analysis summary
estimate, and the diagonal lines pseudo 95% conﬁdence interval limits about the
effect estimate. In the absence of publication bias, studies will be distributed
symmetrically above and below the horizontal line. OR: odds ratio; CI: conﬁdence
interval.
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Duval and Tweedie non-parametric ‘trim and ﬁll’ methodwas used
to adjust for publication bias. Meta-analysis with and without the
‘trim and ﬁll’method did not drawdifferent conclusions, indicating
that our results were statistically robust.
Discussion
Genetic susceptibility to chronic HBV infection has been a
research focus in the scientiﬁc community. Wide variations have
been documented in the frequencies of cytokine polymorphisms
among different healthy populations, including the TNF-a-308
polymorphism, which has been most widely investigated in
healthy populations41 and has been demonstrated to inﬂuence
TNF-a expression.19,42
The studies of TNF-a-308 gene promoter polymorphism in
chronic HBV infection have reported conﬂicting results. The
association between TNF-a-308 gene promoter polymorphism
and outcome of HBV infection has been investigated by several
research groups from different regions of the
world.20,24,31,32,34,35,43 Miyazoe et al.34 reported that inheritance
of IL-10 gene promoter polymorphism was involved in a host
genetic factor that was relevant to disease progression, whilst
polymorphism in the TNF-a-308 gene promoter was not
associated. Similarly, other studies25,31 have shown that poly-
morphisms of TNF-a-308 gene promoter in HBV carriers do not
differ from those in healthy volunteers. Moreover, one study from
Iran reported that TNF-a-308 gene promoter polymorphism was
not associated with development of chronic HBV infection.21 On
the other hand, Kim et al.32 found that TNF-a-308G/A or A/A
polymorphisms were associated with the resolution of HBV
infection. Recently, several researchers fromdifferent geographical
regions of the world demonstrated that the TNF-a-308G/G
polymorphism was associated with either higher risk of persistent
HBV infection or unfavorable prognosis of chronic hepatitis B such
as end-stage liver disease.19,20,25 However, studies with larger
series of patient populations are needed to reveal the signiﬁcance
of the data, since statistically signiﬁcant difference was lost after
Bonferroni correction.
The present meta-analysis of 21 studies, involving a total of
4230 cases and 2905 controls (counting every study’s cases and
controls only once), provides the most comprehensive assessmentso far of the relevance to chronic HBV infection of TNF-a-308 gene
promoter polymorphism. Our results indicate that 308 hetero-
zygote GA carriers had a nearly 27% decreased risk of developing
CHB, homozygote AA carriers had a roughly 72% decreased risk,
and the 308A allele carriers had a nearly 30% decreased risk. The
decreased risks appeared to be more evident in the Mongoloid and
SR groups, but not in the Caucasoid and healthy control groups,
suggesting a possible role of ethnic differences in genetic back-
grounds and the environment they lived in.44 It is also likely that
the observed ethnic differences may be due to chance, because
studieswith small sample sizemay have had insufﬁcient statistical
power to detect a slight effect or may have generated a ﬂuctuated
risk estimate.45 Considering the limited studies and population
numbers of Caucasoids included in the meta-analysis, our results
should be interpreted with caution.
Heterogeneity is a potential problem when interpreting the
results of all meta-analyses.46 Signiﬁcant between-study hetero-
geneity existed in all comparisons except for Caucasoids.
The important factor contributing to the heterogeneity was that
the genotype distribution of controls in several stu-
dies16,18,19,23,26,27,35 did not follow Hardy–Weinberg equilibrium,
indicating that these groups might not represent the general
population very well.
Some limitations of this meta-analysis should be acknowl-
edged. Firstly, the associations were investigated in all kinds of
cases (asymptomatic carriers, chronic hepatitis B, liver cirrhosis),
and theremay be speciﬁc genetic effects among these cases, butwe
could not obtain enough information to further estimate these
effects. Secondly, in the subgroup analyses, the number of
Caucasoids was relatively small, not having enough statistical
power to explore the real association. Thirdly, our results were
based on unadjusted estimates; a more precise analysis should be
conducted with individual data, which would allow for the
adjustment by other co-variates including age, ethnicity, family
history, environmental factors, and lifestyle.
Despite these limitations, this meta-analysis suggests that TNF-
a-308A allele is a protective factor for chronic HBV infection,
especially in the Mongoloid and SR control groups. However, it is
necessary to conduct large trials using standardized unbiased
methods, homogeneous CHB patients and well matched controls,
with the assessors blinded to the data. Moreover, gene–gene and
gene–environment interactions should also be considered in the
analysis. Such studies taking these factors into account may
eventually lead to a better, more comprehensive understanding of
the association between TNF-a-308 gene promoter polymorphism
and chronic HBV infection.
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